Neurological diseases and cancers would greatly benefit from the use of highly potent and specific pharmaceuticals. Active or passively targeted nanomedicines are the only technologies to-date to have shown promise in non-invasive delivery across the blood-brain barrier. Carbohydrate nanoparticles have received interest in this respect due to their hydrophilicity, biodegradability, biocompatibility and ability for large scale manufacture. Chitosan nanomedicines have shown ability to deliver drugs, peptides/proteins and genetic drugs after intravenous, nasal and oral administration in preclinical proof of concept studies resulting in enhanced brain levels and pharmacodynamics responses. Pullulan, dextran and cellulose nanocrystals are emerging technologies that warrant further research to elicit novel delivery systems for overcoming the blood-brain barrier.
|Title of host publication||Nanotechnology and the brain|
|Publication status||Published - 1 Oct 2016|